About Alladapt
Alladapt is a company based in Menlo Park (United States) founded in 2018 by Kari Nadeau. Alladapt has raised $179 million across 3 funding rounds from investors including Novartis, Hercules Capital and Enavate Sciences. The company has 1 employees as of December 31, 2024. Alladapt operates in a competitive market with competitors including PureTech Health, Dren Bio, Adagene, Stallergenes Greer and IgGenix, among others.
- Headquarter Menlo Park, United States
- Employees 1 as on 31 Dec, 2024
- Founders Kari Nadeau
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alladapt Immunotherapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$179 M (USD)
in 3 rounds
-
Latest Funding Round
Not available
-
Investors
Novartis
& 6 more
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Alladapt
Unlock access to complete
Funding Insights of Alladapt
Alladapt has successfully raised a total of $179M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alladapt
Alladapt has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Hercules Capital and Enavate Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt financing is provided to companies in multiple sectors.
|
Locked | Locked | Locked | |
|
Investment partnerships are built and principal investments are made by B-FLEXION.
|
Locked | Locked | Locked | |
|
Venture capital investments are focused on food allergy solutions.
|
Locked | Locked | Locked |
Investor details for Alladapt
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alladapt
Investment portfolio details for Alladapt
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alladapt
Detailed financials for Alladapt
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alladapt Comparisons
Peer comparison for Alladapt
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alladapt
Alladapt operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PureTech Health, Dren Bio, Adagene, Stallergenes Greer and IgGenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| Locked | Locked | Locked |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| Locked | Locked | Locked |
Immunotherapy antibodies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Allergen immunotherapies for respiratory allergies are developed.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for food allergies are developed via antibody platforms.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics are developed for cancer treatment.
|
Detailed competitors of Alladapt
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alladapt
Complete news archive for Alladapt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alladapt
Alladapt was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Alladapt is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Alladapt is a funded company, having raised a total of $179M across 3 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Alladapt is 1.
Alladapt was founded in 2018 and is based in Menlo Park, United States. Therapeutics are developed by the company for the treatment of food allergies, including a single investigational oral immunotherapy known as ADP101. This approach targets common allergens such as cows milk, eggs, tree nuts, peanuts, and shellfish. Prescription options are offered to manage a broad spectrum of food-related sensitivities in the biotechnology sector.
Alladapt's top competitors include Dren Bio, PureTech Health and Adagene.
Alladapt has 7 investors. Key investors include Novartis, Hercules Capital, Enavate Sciences, B-FLEXION, and AllerFund.